| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Guus A M S van Dongen | |
| Sophie E M Veldhuijzen van Zanten | |||
| Ilanah J Pruis | |||
| P2860 | cites work | Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography | Q48867303 |
| Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor | Q48946528 | ||
| Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy | Q49506151 | ||
| Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/CT in patients with glioma | Q49908804 | ||
| 18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy. | Q50073906 | ||
| Targeted Alpha Therapy of mCRPC with 225Actinium-PSMA-617: Swimmer-Plot analysis suggests efficacy regarding duration of tumor-control | Q50077321 | ||
| In-vivo imaging of blood-brain barrier permeability using positron emission tomography with 2-amino-[3-11C]isobutyric acid | Q50209483 | ||
| Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding | Q50210696 | ||
| Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. | Q50472710 | ||
| Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody. | Q52663401 | ||
| Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. | Q52715248 | ||
| 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. | Q52981848 | ||
| An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. | Q53225227 | ||
| The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma. | Q55457483 | ||
| Toward radioguided surgery with β- decays: uptake of a somatostatin analogue, DOTATOC, in meningioma and high-grade glioma. | Q55460465 | ||
| TSPO expression in brain tumours: is TSPO a target for brain tumour imaging? | Q26748489 | ||
| The molecular biology of cancer | Q28199928 | ||
| Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. | Q30596682 | ||
| Clinical applications of choline PET/CT in brain tumors | Q30851829 | ||
| Imaging biomarkers in primary brain tumours | Q30880129 | ||
| Non-invasive metabolic imaging of brain tumours in the era of precision medicine | Q31115540 | ||
| Molecular mechanisms of copper homeostasis | Q33698698 | ||
| Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy | Q33838502 | ||
| Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging | Q34101149 | ||
| Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas | Q34175221 | ||
| (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives | Q34188331 | ||
| Radiolabeled amino acids: basic aspects and clinical applications in oncology | Q34241672 | ||
| Cancer heterogeneity: implications for targeted therapeutics | Q34321565 | ||
| L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors | Q34497164 | ||
| Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy | Q34517660 | ||
| (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients | Q35266784 | ||
| Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival | Q35557989 | ||
| Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. | Q35582767 | ||
| Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo | Q35606075 | ||
| Molecular targeted α-particle therapy for oncologic applications | Q35814989 | ||
| Transport across the blood-brain barrier: stereoselectivity and PET-tracers. | Q35893819 | ||
| The promise of immuno-PET in radioimmunotherapy | Q36011321 | ||
| Study of LAT1 Expression in Brain Metastases: Towards a Better Understanding of the Results of Positron Emission Tomography Using Amino Acid Tracers | Q36045175 | ||
| The extracellular space and matrix of gliomas | Q36263108 | ||
| High-uptake areas on positron emission tomography with the hypoxic radiotracer (18)F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia | Q36322855 | ||
| Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole | Q36962899 | ||
| Immuno-PET: a navigator in monoclonal antibody development and applications. | Q37047713 | ||
| [¹¹C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches | Q37083488 | ||
| Companion diagnostics-a tool to improve pharmacotherapy | Q37583823 | ||
| Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system. | Q37589387 | ||
| Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. | Q37706172 | ||
| Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases | Q37714940 | ||
| Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | Q37819809 | ||
| Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma | Q48151456 | ||
| Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas | Q48182483 | ||
| Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer | Q48190592 | ||
| Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer | Q48252174 | ||
| The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms | Q48300380 | ||
| The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study. | Q48306923 | ||
| Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. | Q48362188 | ||
| Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis | Q48429402 | ||
| Immunohistochemical expression of peripheral benzodiazepine receptors in human astrocytomas and its correlation with grade of malignancy, proliferation, apoptosis and survival | Q48462593 | ||
| Taxonomy of CNS Tumours; A Series of Three Short Reviews on the WHO 2016 Classification and Beyond. | Q48514553 | ||
| (18)F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors | Q48535416 | ||
| ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas | Q48673004 | ||
| Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT. | Q48681387 | ||
| Imaging of Brain Tumors with Copper-64 Chloride: Early Experience and Results. | Q48712366 | ||
| 13N-NH3: a selective contrast-enhancing tracer for brain tumor | Q48843546 | ||
| 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report | Q48859817 | ||
| PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site. | Q55484944 | ||
| PET imaging in glioma: techniques and current evidence | Q57291696 | ||
| PET imaging of intra-arterial Zr bevacizumab in mice with and without osmotic opening of the blood-brain barrier: distinct advantage of intra-arterial delivery | Q57471614 | ||
| Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors | Q58124321 | ||
| Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO | Q58751451 | ||
| The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer | Q58914868 | ||
| Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas | Q60921507 | ||
| Diagnostic accuracy of N-ammonia PET, C-methionine PET and F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma | Q64065796 | ||
| Prevalence of hitherto unknown brain meningioma detected on Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of Lu-DOTATATE peptide receptor radionuclide therapy as | Q64098452 | ||
| Synthesis of L- and D-[methyl-11C]methionine | Q69028866 | ||
| Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation | Q72312438 | ||
| Prostate-specific membrane antigen expression in normal and malignant human tissues | Q77553386 | ||
| Clinical characteristics of meningiomas assessed by ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron-emission tomography | Q82536236 | ||
| Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA) | Q83802389 | ||
| A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer | Q90046288 | ||
| Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection | Q90339150 | ||
| New metabolic imaging tools in neuro-oncology | Q90436830 | ||
| PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review | Q90461247 | ||
| The blood-brain barrier and blood-tumour barrier in brain tumours and metastases | Q90641415 | ||
| Principles and current trends in the correlative evaluation of glioma with advanced MRI techniques and PET | Q90958980 | ||
| Imaging Brain Metastasis Patients With 18F-(2S,4R)-4-Fluoroglutamine | Q91283419 | ||
| Brain Access of Monoclonal Antibodies as Imaged and Quantified by 89Zr-Antibody PET: Perspectives for Treatment of Brain Diseases | Q91429079 | ||
| 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study | Q91556874 | ||
| Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET/CT in patients with inoperable meningioma | Q91625419 | ||
| Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study | Q91657129 | ||
| Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients | Q92101215 | ||
| Engineered antibodies: new possibilities for brain PET? | Q92160434 | ||
| Molecular pathology of tumors of the central nervous system | Q92264924 | ||
| PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration | Q92505550 | ||
| MRI-Driven PET Image Optimization for Neurological Applications | Q92649166 | ||
| Will 177Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration | Q92673212 | ||
| Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma | Q93091117 | ||
| Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma | Q93380708 | ||
| Use of positron emission tomography in the evaluation of diffuse intrinsic brainstem gliomas in children | Q37878238 | ||
| PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. | Q37978157 | ||
| PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. | Q38024205 | ||
| Value of 11C-methionine PET in imaging brain tumours and metastases | Q38066701 | ||
| Quantitation of blood-brain barrier permeability by positron emission tomography | Q38243105 | ||
| Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. | Q38364006 | ||
| Overcoming the blood-brain tumor barrier for effective glioblastoma treatment | Q38384505 | ||
| TSPO PET for glioma imaging using the novel ligand (18)F-GE-180: first results in patients with glioblastoma | Q38640193 | ||
| Amino acid PET and MR perfusion imaging in brain tumours. | Q38691946 | ||
| The role of bevacizumab in the treatment of glioblastoma | Q38773624 | ||
| Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview | Q39104249 | ||
| The Microenvironmental Landscape of Brain Tumors | Q39178065 | ||
| Molecular Drug Imaging: 89Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. | Q39264962 | ||
| ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI. | Q39761792 | ||
| Immunolocalization of full-length NK1 tachykinin receptors in human tumors | Q40285095 | ||
| PET: blood flow and oxygen consumption in brain tumors | Q40531129 | ||
| Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. | Q41045513 | ||
| Osmotic opening of the blood-brain barrier and local cerebral glucose utilization | Q41602741 | ||
| Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake | Q42702315 | ||
| 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery | Q43059537 | ||
| Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors in pediatric epilepsy patients using 18F-FDG and 11C-methionine pet. | Q43097941 | ||
| Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC. | Q43164807 | ||
| Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas | Q43169865 | ||
| Cerebellopontine angle schwannoma on C-11 acetate PET/CT. | Q43256288 | ||
| Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers | Q43830072 | ||
| PET study of carbon-11-PK 11195 binding to peripheral type benzodiazepine sites in glioblastoma: a case report. | Q43836608 | ||
| Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. | Q44240328 | ||
| Prediction of survival in glioma patients by means of positron emission tomography | Q44605744 | ||
| Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionine | Q44632449 | ||
| Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value | Q45017009 | ||
| Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. | Q45144563 | ||
| Methionine and glucose metabolism of central neurocytoma: a PET study | Q45152003 | ||
| 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. | Q45889029 | ||
| TOTAL-BODY PET: MAXIMIZING SENSITIVITY TO CREATE NEW OPPORTUNITIES FOR CLINICAL RESEARCH AND PATIENT CARE. | Q46035229 | ||
| 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma | Q46045225 | ||
| Expression of EAAT-1 distinguishes choroid plexus tumors from normal and reactive choroid plexus epithelium | Q46090086 | ||
| C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience | Q46192605 | ||
| Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole | Q46194633 | ||
| A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma | Q46256029 | ||
| Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. | Q46270281 | ||
| 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. | Q46548869 | ||
| 18F-FDG PET of common enhancing malignant brain tumors | Q46585118 | ||
| Misdiagnoses of 11C-choline combined with 18F-FDG PET imaging in brain tumours | Q46720763 | ||
| Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. | Q46723808 | ||
| First-in-human HER2-targeted imaging using 89Zr-pertuzumab PET/CT: Dosimetry and clinical application in patients with breast cancer | Q47965803 | ||
| Standardized uptake value in high uptake area on positron emission tomography with 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma | Q47966116 | ||
| The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients? | Q48012936 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P577 | publication date | 2020-02-04 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors | |
| P478 | volume | 21 |
Search more.